Paul Badawi Sells 11,870 Shares of Sight Sciences (NASDAQ:SGHT) Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CEO Paul Badawi sold 11,870 shares of the stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $7.48, for a total value of $88,787.60. Following the sale, the chief executive officer owned 5,925,276 shares of the company’s stock, valued at $44,321,064.48. This trade represents a 0.20% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Paul Badawi also recently made the following trade(s):

• On Friday, January 2nd, Paul Badawi sold 25,356 shares of Sight Sciences stock. The stock was sold at an average price of $7.43, for a total value of $188,395.08.

Sight Sciences Stock Down 0.4%

Shares of Sight Sciences stock opened at $7.44 on Thursday. Sight Sciences, Inc. has a 12-month low of $2.03 and a 12-month high of $9.24. The firm has a market capitalization of $393.35 million, a PE ratio of -8.27 and a beta of 2.42. The company has a quick ratio of 8.93, a current ratio of 9.60 and a debt-to-equity ratio of 0.62. The stock’s fifty day moving average is $7.57 and its 200-day moving average is $5.15.

Sight Sciences (NASDAQ:SGHT) last released its quarterly earnings results on Wednesday, September 8th. The company reported ($0.81) earnings per share for the quarter. The company had revenue of $12.54 million during the quarter. Sight Sciences had a negative net margin of 60.63% and a negative return on equity of 61.59%. Equities analysts anticipate that Sight Sciences, Inc. will post -0.99 earnings per share for the current year.

Institutional Trading of Sight Sciences

Several hedge funds and other institutional investors have recently modified their holdings of SGHT. Long Focus Capital Management LLC boosted its position in Sight Sciences by 1.3% during the third quarter. Long Focus Capital Management LLC now owns 3,193,305 shares of the company’s stock valued at $10,985,000 after purchasing an additional 41,797 shares during the last quarter. Millennium Management LLC raised its stake in shares of Sight Sciences by 145.2% during the 3rd quarter. Millennium Management LLC now owns 133,846 shares of the company’s stock worth $460,000 after purchasing an additional 79,265 shares in the last quarter. Alliancebernstein L.P. lifted its holdings in shares of Sight Sciences by 5.5% during the 3rd quarter. Alliancebernstein L.P. now owns 34,380 shares of the company’s stock valued at $118,000 after buying an additional 1,800 shares during the last quarter. BNP Paribas Financial Markets grew its stake in shares of Sight Sciences by 99.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 7,579 shares of the company’s stock valued at $26,000 after buying an additional 3,785 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in Sight Sciences by 1.0% in the third quarter. Dimensional Fund Advisors LP now owns 303,634 shares of the company’s stock worth $1,045,000 after buying an additional 3,051 shares during the last quarter. 55.51% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently commented on SGHT shares. Citigroup raised their price objective on shares of Sight Sciences from $5.50 to $9.10 and gave the stock a “neutral” rating in a research note on Thursday, December 11th. UBS Group increased their target price on Sight Sciences from $7.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday, December 23rd. Piper Sandler set a $9.00 target price on Sight Sciences in a research report on Monday. Lake Street Capital upped their price target on Sight Sciences from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Tuesday, October 21st. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Sight Sciences in a research note on Monday, December 29th. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $8.30.

Key Headlines Impacting Sight Sciences

Here are the key news stories impacting Sight Sciences this week:

• Positive Sentiment: Piper Sandler upgraded Sight Sciences to Overweight, which can attract buying from institutions and retail investors and support near-term positive sentiment. Read More.
• Neutral Sentiment: Key insiders still hold large stakes (CEO Paul Badawi ~5.9M shares; CTO David Badawi ~1.9M shares), which suggests ongoing long-term alignment despite recent sales and may limit fears of full insider exit. Read More.
• Negative Sentiment: Multiple executives (CEO, CTO, CFO, EVP and other insiders) disclosed sales between Jan. 2–6 totaling roughly $0.48M in proceeds. The clustered timing and size of the trades — even though each is a small percentage of holdings — can create short-term downward pressure or signal near‑term liquidity needs. Read More.

Sight Sciences Company Profile

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.